Talk:Post-exposure prophylaxis

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Medicine (Rated Start-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
 
WikiProject AIDS
WikiProject icon This article is part of WikiProject AIDS, an attempt to build a comprehensive, detailed, and accessible guide to AIDS, HIV, and related topics on Wikipedia. If you would like to participate in the project, you can choose to edit this article, or visit the project page for more information.
 

Herpes[edit]

The section on Herpes seems to be mixing up post-exposure prophylaxis (preventing getting infected with the virus) with suppression of the infection (already having it but reducing outbreaks). I've made a minimal edit for the moment, but this section needs to be revised more and the presentation of the issue needs to be more clear. MartinezMD (talk) 01:18, 25 August 2011 (UTC)

How deeply should we look into this? My first thought is that you are exactly right and that this information should not be on this page at all. Should the entire section just be moved elsewhere, like to a herpes treatment page? Blue Rasberry (talk) 04:33, 25 August 2011 (UTC)
Whatever we have needs to be accurate. I'll cut it out of there and paste it here for now. We can repair it and paste back after revision. I'm sure the the Herpes treatment article (haven't looked really but this is rudimentary stuff) already has itself covered. We need to address the topic even if the sources simply say there is no current prophylaxis (or perhaps there is - we need to look).MartinezMD (talk) 05:26, 25 August 2011 (UTC)


The section below has been removed from the article and needs corrective revision. See above discussion:

Herpes[edit]

Several studies in humans and mice provide evidence that treatment with the antiviral drug famciclovir soon after the first infection with herpes can significantly lower the chance of future symptomatic outbreaks of herpes. Use of famciclovir in this manner has been shown to reduce the amount of latent herpes virus in the neural ganglia.[1][2][3] A review of human subjects treated for five days with famciclovir 250 mg three times daily during their first herpes episode found that only 4.2 percent experienced a recurrence within six months after the first outbreak, a fivefold decrease compared to the 19 percent recurrence in acyclovir-treated patients.[4]

Prophylaxis for herpes in this or similar dosage regimes has yet to find mainstream adoption. Some doctors and patients have opted for off-label use. One suggested regime is famciclovir at 10–20 mg/kg per day for 5–14 days, with treatment to commence as soon as possible after the first herpes infection(not the first symptoms or outbreak), and the most effective time for initiating treatment to be five days or less after the initial herpes infection.[5]

Request: A mention of rabies PEP will be greatly useful.[edit]

71.92.208.8 (talk) 02:44, 6 January 2013 (UTC)

  1. ^ The effects of antiviral therapy on the distribution of herpes simplex virus type 1 to ganglionic neurons and its consequences during, immediately following and several months after treatment"[1]"
  2. ^ Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study"[2]"
  3. ^ Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy"[3]"
  4. ^ Observation May Indicate A Possible Clinical Effect On Latency"[4]"
  5. ^ Thackray AM, Field HJ. (1996). "Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency". J. Infect. Dis. 173 (2): 291–299. PMID 8568288.